# Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL

> **NCT03766516** · — · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 90 (actual)

## Conditions studied

- Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03766516
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03766516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03766516, "Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03766516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*